Omeros Corporation News Releases https://investor.omeros.com/ Omeros Corporation News Releases en Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-announces-assignment-rapporteurs-european – Preparations Continue for Submission of BLA in the U.S. and MAA in Europe – SEATTLE --(BUSINESS WIRE)--Jun. 5, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that the European Medicines Agency (EMA) has appointed rapporteurs for the company’s marketing authorization application (MAA) Wed, 05 Jun 2019 08:30:00 -0400 Omeros Corporation News Releases 11701 Omeros to Present at the UBS Global Healthcare Conference https://investor.omeros.com/news-releases/news-release-details/omeros-present-ubs-global-healthcare-conference SEATTLE --(BUSINESS WIRE)--May 15, 2019-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, May 22, 2019 at Wed, 15 May 2019 07:00:00 -0400 Omeros Corporation News Releases 11681 Omeros Corporation Reports First Quarter 2019 Financial Results https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-reports-first-quarter-2019-financial-results – Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 9, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan Thu, 09 May 2019 16:02:00 -0400 Omeros Corporation News Releases 11661 Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting https://investor.omeros.com/news-releases/news-release-details/clinical-study-showing-reduced-incidence-cystoid-macular-edema - Cataract surgery performed using OMIDRIA had lower rates of CME than cataract surgery using postoperative steroids- SEATTLE --(BUSINESS WIRE)--May 7, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced the results of a real-world clinical study showing that its FDA -approved ophthalmic drug Tue, 07 May 2019 09:04:00 -0400 Omeros Corporation News Releases 11656 Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019 https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-announce-first-quarter-2019-financial-results SEATTLE --(BUSINESS WIRE)--May 6, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019 , on Thursday, May 9, 2019 , after the market closes. Omeros management will host a conference call Mon, 06 May 2019 18:01:00 -0400 Omeros Corporation News Releases 11646 Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-announces-presentation-omidriar-real-world SEATTLE --(BUSINESS WIRE)--May 1, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced that the results of an investigator-sponsored real-world study of its FDA -approved ophthalmic drug OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% will be presented at the American Wed, 01 May 2019 08:30:00 -0400 Omeros Corporation News Releases 11636 Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-announces-ebmt-case-report-resolution -- Growing Identification of HSCT-TMA a Focus of Recent Annual Meeting of the European Society for Blood and Marrow Transplantation -- SEATTLE --(BUSINESS WIRE)--Apr. 3, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced the recent presentation of a case report describing resolution of Wed, 03 Apr 2019 08:30:00 -0400 Omeros Corporation News Releases 11621 Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-announces-upcoming-educational-event-annual --Session Will Focus on Diagnosis of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy-- SEATTLE --(BUSINESS WIRE)--Mar. 19, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and Tue, 19 Mar 2019 08:30:00 -0400 Omeros Corporation News Releases 11616 Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-reports-fourth-quarter-and-year-end-2018 – Conference Call Today at 8:30 a.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan Fri, 01 Mar 2019 07:30:00 -0500 Omeros Corporation News Releases 11581 Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019 https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-announce-fourth-quarter-and-year-end-2018 SEATTLE --(BUSINESS WIRE)--Feb. 26, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018 , on Friday, March 1, 2019 , before the market opens. Tue, 26 Feb 2019 07:00:00 -0500 Omeros Corporation News Releases 11571